Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumourReport as inadecuate

Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour - Download this document for free, or read online. Document in PDF available to download.

European Journal of Nuclear Medicine and Molecular Imaging

, 38:1854

First Online: 23 June 2011Received: 14 February 2011Accepted: 07 June 2011


PurposePositron emission tomography PET using 6-Ffluoro-L-dihydroxyphenylalanine F-dopa has an excellent sensitivity to detect carcinoid tumour lesions. F-dopa tumour uptake and the levels of biochemical tumour markers are mediated by tumour endocrine metabolic activity. We evaluated whether total F-dopa tumour uptake on PET, defined as whole-body metabolic tumour burden WBMTB, reflects tumour load per patient, as measured with tumour markers.

MethodsSeventy-seven consecutive carcinoid patients who underwent an F-dopa PET scan in two previously published studies were analysed. For all tumour lesions mean standardised uptake values SUVs at 40% of the maximal SUV and tumour volume on F-dopa PET were determined and multiplied to calculate a metabolic burden per lesion. WBMTB was the sum of the metabolic burden of all individual lesions per patient. The 24-h urinary serotonin, urine and plasma 5-hydroxindoleacetic acid 5-HIAA, catecholamines norepinephrine, dopamine and their metabolites, measured in urine and plasma, and serum chromogranin A served as tumour markers.

ResultsAll but 1 were evaluable for WBMTB; 74 patients had metastatic disease. F-dopa PET detected 979 lesions. SUVmax on F-dopa PET varied up to 29-fold between individual lesions within the same patients. WBMTB correlated with urinary serotonin r = 0.51 and urinary and plasma 5-HIAA r = 0.78 and 0.66. WBMTB also correlated with urinary norepinephrine, epinephrine, dopamine and plasma dopamine, but not with serum chromogranin A.

ConclusionTumour load per patient measured with F-dopa PET correlates with tumour markers of the serotonin and catecholamine pathway in urine and plasma in carcinoid patients, reflecting metabolic tumour activity.

KeywordsF-dopa PET Carcinoid tumour Whole-body metabolic tumour burden 5-HIAA  Download fulltext PDF

Author: Helle-Brit Fiebrich - Johan R. de Jong - Ido P. Kema - Klaas Pieter Koopmans - Wim Sluiter - Rudi A.J.O. Dierckx - Anne


Related documents